ADCYAP1 and migraine disorder: We further investigated potential therapeuticmodulation by microinjecting naratriptan, a 5-HT1B/D/F receptor agonistwidely used in migraine treatment; PACAP38, a peptide that, when administeredintravenously, induces delayed migraine-like headaches in susceptible migrainepatients (33); and a DAD2/D3 receptor agonist, known to inhibit trigeminovascularresponses in animals (34).